Remodeling of the Tumor Microenvironment and Clinical Outcomes Following ONCOS-102 and Pembrolizumab in Anti–PD-1–Resistant Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma
Clin. Cancer Res 2022 Sep 16;[EPub Ahead of Print], A Shoushtari, AJ Olszanski, M Nyakas, TJ Hornyak, JD Wolchok, V Levitsky, L Kuryk, TB Hansen, M JäderbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.